Bioequivalence refers to the relationship between two pharmaceutical products that contain the same active ingredient and are expected to have similar effects in the body. This concept is crucial for ensuring that generic drugs, which are often less expensive, can be safely used as alternatives to brand-name medications. Regulatory agencies, like the FDA, require bioequivalence studies to confirm that the generic version releases the active ingredient into the bloodstream at a similar rate and extent as the original product. To establish bioequivalence, researchers conduct clinical trials comparing the two formulations. They measure key pharmacokinetic parameters, such as Cmax (maximum concentration) and Tmax (time to reach maximum concentration), to determine if the differences in absorption are within acceptable limits. If the results show that the two products behave similarly in the body, they are considered bioequivalent, allowing for the generic version to be marketed.